Unipolar Depression | Disease Landscape and Forecast | G7 | 2021

The unipolar depression market is crowded and highly genericized. The prominent use of SSRIs and, to a lesser extent, SNRIs as early-line treatments contributes to the challenges branded therapies face when entering this market. Newer-to-market brands (e.g., Lundbeck / Takeda’s Trintellix / Brintellix, Lundbeck / Otsuka Pharmaceutical’s Rexulti / Rxulti) largely compete for use in treatment-resistant depression (TRD) patients, who make up one-third of the major depressive disorder population. The most recent entrant to the depression market, Janssen’s Spravato, offers the fastest onset of therapeutic effect among the approved therapies—fulfilling a key unmet need—but its use for TRD is constrained by multiple factors. Because of remaining unmet needs, physicians will continue to look to emerging therapies—many of which offer novel mechanisms of action—as potential future treatments in this market.


  • What factors drive and constrain the use of branded antidepressants and atypical antipsychotics? What branded therapy is expected to experience the greatest commercial success during the forecast period?
  • Given the crowded, highly genericized unipolar depression market, what is the commercial potential of key emerging therapies for unipolar depression?
  • What are the greatest areas of unmet need in the treatment of unipolar depression, and how are therapies in late-phase development expected to address these unmet needs?


Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 24 country-specific interviews with thought-leading psychiatrists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Prevalence of unipolar depression by country, segmented by major depressive disorder, minor depression, and dysthymia; diagnosed / drug-treated prevalence of unipolar depression by country.

Forecast: 10-year, annualized, drug-level sales and patient share of key unipolar depression therapies in 2020-2030, segmented by brands / generics.

Emerging therapies: Phase III/PR: 5 drugs. Coverage of select early-phase products.

Key companies: AbbVie, AstraZeneca, Axsome Therapeutics, Biogen, Gedeon Richter, GlaxoSmithKline, Janssen, Lundbeck, Luye Pharma Group, Otsuka Pharmaceutical, Pfizer, Relmada Therapeutics, Sage Therapeutics, Shionogi, Sumitomo Dainippon, Sunovion, Takeda.

Key drugs: Ansofaxine hydrochloride, aripiprazole, bupropion HCl SR/XR, duloxetine, escitalopram, Latuda (lurasidone), quetiapine IR/XR, Rexulti / Rxulti (brexpiprazole), Spravato (esketamine), Trintellix / Brintellix (vortioxetine), venlafaxine IR/XR, Vraylar / Reagila (cariprazine), AXS-05, REL-1017, seltorexant, zuranolone (SAGE-217).


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Login to access report